Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $56.00 Consensus Target Price from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned an average recommendation of "Buy" from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $56.00.

A number of research firms have recently weighed in on TARS. Guggenheim reissued a "buy" rating on shares of Tarsus Pharmaceuticals in a report on Monday, February 10th. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday, November 15th. Finally, Barclays increased their target price on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an "overweight" rating in a report on Monday, January 27th.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in TARS. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company's stock valued at $71,653,000 after purchasing an additional 698,712 shares during the period. Lord Abbett & CO. LLC grew its position in shares of Tarsus Pharmaceuticals by 115.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock valued at $70,873,000 after buying an additional 685,111 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock valued at $14,477,000 after buying an additional 420,057 shares during the period. Gilder Gagnon Howe & Co. LLC raised its position in shares of Tarsus Pharmaceuticals by 5,636.3% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 404,237 shares of the company's stock worth $22,383,000 after acquiring an additional 397,190 shares during the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Tarsus Pharmaceuticals in the third quarter worth approximately $10,587,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS traded down $2.01 during trading hours on Wednesday, reaching $50.22. 315,387 shares of the stock were exchanged, compared to its average volume of 545,759. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.18 and a beta of 1.01. The stock's fifty day simple moving average is $52.07 and its 200 day simple moving average is $41.68. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.